Restore Medical is a medical device company focused on treating congestive heart failure, specifically targeting patients with left ventricle failure. Founded in 2016 and based in Or Yehuda, Israel, the company offers ContraBand, a catheter-delivered implant designed for placement in the pulmonary arteries. This innovative device aims to enhance left ventricle ejection fraction, decrease mitral regurgitation, and restore favorable ventricular geometry. By improving patient outcomes, Restore Medical's solutions contribute to a better quality of life and aim to reduce the rates of hospital readmission among affected individuals.
Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection tasks. Tando employs independent AI-based navigation and a patented ceiling docking system, providing real-time coverage and utilizing predictive analysis to reduce false alarms. The drone autonomously collects and analyzes data, promoting consistent quality and enhancing safety. This innovative solution combines robotics with advanced AI capabilities, offering a cost-effective and efficient approach to intelligent indoor monitoring. By collaborating with leaders in the security and smart building sectors, Indoor Robotics aims to transform the landscape of indoor surveillance and inspection through improved area coverage and response times.
PhoneOptika specializes in the development of advanced thin optical film technology aimed at enhancing user experience and safety while interacting with digital displays. The company focuses on creating innovative products that improve the quality of viewing on devices such as mobile phones, tablets, and control monitors. By prioritizing both user engagement and safety, PhoneOptika is committed to delivering solutions that significantly enhance the way individuals interact with digital technology.
EZMEMS is an automation technology platform that specializes in developing smart plastic sensors designed for the Internet of Things (IoT) applications. The company's primary offering is a fully integrated multi-sensing system on a plastic chip, which allows for seamless integration into various plastic products. EZMEMS focuses on creating small, wireless, battery-free, and low-cost sensors that enhance sensor fusion systems for improved sensing, analytics, and insights. This technology provides clients with reliable and economical solutions essential for modern IoT and edge systems, enabling more efficient data collection and analysis.
NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.
Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.
GrayMatters Health delivers beyond the pill digital therapeutics for mental disorders through volitional regulation of brain processes.
YonaLink operates a global network of over 30,000 medical centers, focusing on the collection and management of clinical trial data. The company offers a platform that streamlines the migration of clinical research data from electronic health records to electronic data capture systems, ensuring a secure and automated process. By enhancing trial efficiency and data quality, YonaLink alleviates the burden on medical center staff and broadens access to innovative patient care opportunities. Its solutions also aim to accelerate drug and medical device development while promoting patient diversity and enrollment in clinical trials, ultimately enabling healthcare providers and researchers to achieve faster and more accurate data capture.
Filterlex Medical Ltd. is a medical device startup focused on the cardiovascular field, specifically developing an advanced embolic protection device aimed at reducing the risk of stroke and other complications during catheter-based structural heart procedures. The company's innovative device utilizes next-generation technology to address the limitations of existing products. It is designed to be securely positioned in the aorta, providing comprehensive embolic protection by deflecting, capturing, and removing embolic particles. This approach enables physicians to enhance patient safety during these complex procedures. Currently, Filterlex is seeking seed funding to further advance its development efforts.
BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.
VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.
VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.
Wi-Charge is a developer of innovative wireless power solutions that utilize infrared technology to enable remote charging of electronic devices. Founded in 2010, the company addresses the growing need for efficient power management in the digital age by allowing devices to be powered continuously without the constraints of charging cables or batteries. Its technology is applicable in various environments, including smart retail and smart buildings, where it powers devices such as advertising displays, smart door locks, and security cameras. As Wi-Charge expands its offerings, it aims to serve consumer and commercial markets by providing wireless charging for laptops, tablets, mobile phones, gaming controllers, and light electric vehicles. The company's solutions not only offer cost savings by eliminating the need for cords and batteries but also promote sustainable energy practices, enhancing environmental, social, and governance (ESG) ratings.
PlasFree is a medical device company focused on developing ClearPlasma, an innovative solution aimed at improving the treatment of massive bleeding. Founded in 2017 and based in Nazareth, Israel, PlasFree's ClearPlasma device modifies human plasma by extracting specific proteins, such as fibrinolytic proteins and pepsinogen, which play a role in blood clot dissolution. By enhancing the coagulation properties of plasma, the device enables healthcare professionals to deliver safer and more effective treatments for excessive bleeding. ClearPlasma can be integrated into conventional apheresis systems, allowing for the efficient production of plasma products tailored for critical medical situations. The company's mission is to revolutionize bleeding management and provide improved therapeutic options worldwide.
Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.
PlasFree is a medical device company focused on developing ClearPlasma, an innovative solution aimed at improving the treatment of massive bleeding. Founded in 2017 and based in Nazareth, Israel, PlasFree's ClearPlasma device modifies human plasma by extracting specific proteins, such as fibrinolytic proteins and pepsinogen, which play a role in blood clot dissolution. By enhancing the coagulation properties of plasma, the device enables healthcare professionals to deliver safer and more effective treatments for excessive bleeding. ClearPlasma can be integrated into conventional apheresis systems, allowing for the efficient production of plasma products tailored for critical medical situations. The company's mission is to revolutionize bleeding management and provide improved therapeutic options worldwide.
Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection tasks. Tando employs independent AI-based navigation and a patented ceiling docking system, providing real-time coverage and utilizing predictive analysis to reduce false alarms. The drone autonomously collects and analyzes data, promoting consistent quality and enhancing safety. This innovative solution combines robotics with advanced AI capabilities, offering a cost-effective and efficient approach to intelligent indoor monitoring. By collaborating with leaders in the security and smart building sectors, Indoor Robotics aims to transform the landscape of indoor surveillance and inspection through improved area coverage and response times.
NanoVation provides monitoring solutions for patients with chronic respiratory diseases. NanoVation detects respiratory changes before reaching critical stages. Their aim is to improve the outcomes of patient's respiratory deteriorations by enabling early identification and intervention at home. Their patented technology can identify subtle changes in patient's respiratory condition, enabling healthcare professionals to take proactive measures and prevent patient’s exacerbations and unnecessary hospitalizations. NanoVation was founded by Gregory Shuster.
ZygoFix is a medical device company focused on spine technology. It has developed a three-dimensional printed implant designed to lock the facet joint of the lumbar spine. This innovative device leverages the anatomy of the spine to provide stability, moving away from traditional external screw-based systems. By eliminating the need for pedicle screws, ZygoFix aims to reduce the risks associated with improper screw placement, enhancing patient safety and outcomes in spinal surgeries.
Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).
Respinova specializes in the development of non-invasive devices for the treatment of respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's primary product, the PulseHaler, leverages innovative technology that generates dynamic air pressure pulses. These pulses travel quickly through the airways, creating momentary dilating forces that help open collapsed airways and facilitate mucus clearance. By smoothing and spreading the mucus lining within the airways, the PulseHaler aids in airway clearance and reduces the likelihood of airway re-collapse, providing a significant improvement in treatment options for COPD patients.
Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.
Respinova specializes in the development of non-invasive devices for the treatment of respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's primary product, the PulseHaler, leverages innovative technology that generates dynamic air pressure pulses. These pulses travel quickly through the airways, creating momentary dilating forces that help open collapsed airways and facilitate mucus clearance. By smoothing and spreading the mucus lining within the airways, the PulseHaler aids in airway clearance and reduces the likelihood of airway re-collapse, providing a significant improvement in treatment options for COPD patients.
EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.
EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.
Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.
Kahun operates an online medical platform designed to assist healthcare organizations in improving the clinical intake process. By leveraging artificial intelligence, the platform catalogs clinical information from peer-reviewed medical literature and extracts relevant insights to facilitate informed decision-making by physicians. This approach optimizes the time doctors spend on documentation while enhancing their overall understanding of clinical knowledge. Ultimately, Kahun aims to improve clinical outcomes by providing a transparent and explainable system that supports efficient and effective diagnosis.
Clarifruit is disrupting the $2 trillion Fresh Produce supply chain by creating the world’s first automatic QC & data analytics platform. The Fresh Produce industry is experiencing a staggering 45% waste, caused by multiple reasons and market failures along the chain, in which the common denominator is lack of objective and consistent quality standards as well as hard-data upon to make decisions. Clarifruit’s QC platform can automatically identify, collect, and analyze real-time data about the fresh produce external and internal attributes. Solution results in objective, consistent, and cost- effective inspection that not only increases inspector productivity by x3 and reduces customer's current waste, but also empowers the world’s Fresh Produce growers, wholesalers, and retailers to make decisions based on high-quality data, resulting in better match of quality of supply to customer demand and ultimately favorable revenue opportunities.
MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.
Trisol Medical specializes in developing innovative medical devices for the treatment of tricuspid regurgitation. The company focuses on its transcatheter tricuspid replacement valve, which features a nitinol frame and specially designed leaflets aimed at effectively addressing tricuspid regurgitation while preserving the function of the right ventricle. Through its advanced technology, Trisol Medical offers comprehensive solutions for managing tricuspid regurgitation and right ventricle dysfunction, enhancing patient outcomes in the field of cardiac care.
Trisol Medical specializes in developing innovative medical devices for the treatment of tricuspid regurgitation. The company focuses on its transcatheter tricuspid replacement valve, which features a nitinol frame and specially designed leaflets aimed at effectively addressing tricuspid regurgitation while preserving the function of the right ventricle. Through its advanced technology, Trisol Medical offers comprehensive solutions for managing tricuspid regurgitation and right ventricle dysfunction, enhancing patient outcomes in the field of cardiac care.
NanoVation provides monitoring solutions for patients with chronic respiratory diseases. NanoVation detects respiratory changes before reaching critical stages. Their aim is to improve the outcomes of patient's respiratory deteriorations by enabling early identification and intervention at home. Their patented technology can identify subtle changes in patient's respiratory condition, enabling healthcare professionals to take proactive measures and prevent patient’s exacerbations and unnecessary hospitalizations. NanoVation was founded by Gregory Shuster.
Cubbit is a geo-distributed cloud enabler that transforms underutilized resources at the edge of the internet into B2B cloud services. Its software can operate on existing resources, in the cloud, or at the edge, allowing for the creation of a seamless data domain. This innovative platform offers highly resilient cloud object storage while maintaining client sovereignty over data. Cubbit enables businesses to reduce storage costs by up to 80% and minimize their cloud carbon footprint, catering to traditional use cases like backup and addressing modern demands related to Edge computing, Multi-cloud environments, and Data Sovereignty. With Cubbit, companies regain full control over their data, infrastructure, and costs, all with a simple setup process that requires no upfront investment.
VAYAVISION is a raw data fusion and perception system providing the most reliable environmental model for autonomous vehicles